

**Role of Brain Natriuretic Peptide in
Detection of Right Ventricular Dysfunction
and Pulmonary Hypertension among
Children with Chronic Lung Diseases**

Thesis

*Submitted for Partial Fulfillment of the Master Degree in
Pediatrics*

By

Nora Waheed Hassan Mohamed

M.B.B.ch (2009)

Faculty of Medicine-Ain Shams University

Under supervision of

Dr. Terez Boshra Kamel

Assistant Professor of Pediatrics

Faculty of Medicine - Ain-Shams University

Dr. Waleed Mohamed Elguindy

Assistant Professor of Pediatrics

Faculty of Medicine - Ain-Shams University

Dr. Enas Samir Nabih

Assistant Professor of Biochemistry

Faculty of Medicine - Ain-Shams University

*Faculty of Medicine
Ain Shams University*

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and
profound gratitude to **Dr. Terez Boshra
Kamel**, Assistant Professor of Pediatrics - Faculty
of Medicine- Ain Shams University for her keen
guidance, kind supervision, valuable advice and
continuous encouragement, which made possible the
completion of this work.*

*I am also delighted to express my deepest
gratitude and thanks to **Dr. Waleed Mohamed
Elquindy**, Assistant Professor of Pediatrics,
Faculty of Medicine, Ain Shams University, for his
kind care, continuous supervision, valuable
instructions, constant help and great assistance
throughout this work.*

*I am deeply thankful to **Dr. Enas Samir
Nabih**, Assistant Professor of Biochemistry,
Faculty of Medicine, Ain Shams University, for her
great help, active participation and guidance.*

*I would like to express my hearty thanks to all
my family for their support till this work was
completed.*

*Last but not least my sincere thanks and
appreciation to all patients participated in this
study.*

Nora Waheed Hassan Mohamed

List of Contents

Title	Page No.
List of Tables	6
List of Figures	8
List of Abbreviations	9
Abstract	ix
Introduction	2
Aim of the Work	4
Review of Literature	
▪ Chronic Lung Diseases	5
▪ Cardiac Manifestation and Dysfunction in Chronic Pulmonary Disease	30
▪ Brain Natriuretic Peptide	43
Subjects and Methods	49
Results	60
Discussion	77
Summary	98
Conclusion	100
Recommendations	100
References	101
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Classification of pediatric interstitial lung disease by etiology.....	8
Table (2):	Summary of genes involved in the etiology of childhood interstitial lung disease.....	10
Table (3):	Morphological types of bronchiectasis.....	23
Table (4):	Symptoms of acute exacerbation in patient with bronchiectasis;.....	24
Table (5):	The modified Medical Research Council (mMRC) scale for dyspnea grading.....	51
Table (6):	Statistical comparison between PH and non PH according demographic data.....	60
Table (7):	Statistical comparison between PH and nonPH according clinical data.....	61
Table (8):	Statistical comparison between PH and non PH according laboratory data.	62
Table (9):	Comparison between PH and non PH according BNP (pg/ml).	63
Table (10):	Statistical Comparison between IPF and bronchiectasis according BNP.....	64
Table (11):	Comparison between PH and Non PH according to conventional Echo (M-mode) variable.....	65
Table (12):	Statistical comparison (mean±SD) of right ventricular ecocardiographic findings between PH and non PH:	66
Table (13):	Statistical comparison of TDI finding (mean±SD) between PH and Non PH group.	68

List of Tables (cont...)

Table No.	Title	Page No.
Table (14):	Correlation between BNP (pg/ml) and other parameters, using Pearson correlation coefficient of the study groups.....	70
Table (15):	Diagnostic Performance of BNP (pg/ml) in Discrimination of IPF and bronchiectasis.....	72
Table (16):	Diagnostic Performance of BNP (pg/ml) in Discrimination PH and non PH.....	73
Table (17):	Logistic regression analysis of factors affecting BNP (pg/ml).....	74
Table (18):	Comparison between IPF and bronchiectasis according PH.....	75
Table (19):	Statistical comparison between IPF and bronchiectasis according PAP.....	76

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Algorithm for the diagnosis of interstitial lung disease (ILD) presenting after 2 years of age.	12
Fig. (2):	BNP and NT-pro BNP	43
Fig. (3):	The Echocardiographic Vivid E9 machine.	54
Fig. (4):	Boxplot between positive and negative PH according BNP.	63
Fig. (5):	Boxplot between IPF and bronchiectasis according BNP.	64
Fig. (6):	Scatter plot Negative correlation and significant between BNP (pg/ml) and height.	71
Fig. (7):	Scatter plot Negative correlation and significant between BNP (pg/ml) and cyanosis.	71
Fig. (8):	Diagnostic Performance of IPF and bronvchiectesisin Discrimination of BNP (pg/ml).	72
Fig. (9):	Diagnostic Performance of PH and non PH in Discrimination of BNP (pg/ml).	73
Fig. (10):	Comparison between IPF and bronchiectasis according PH	75
Fig. (11):	Statistical comparison between IPF and bronchiectasis according PAP.	76

List of Abbreviations

Abb.	Full term
<i>6MWT</i>	<i>6-min walk test</i>
<i>A'</i>	<i>Annular peak velocity during late diastole.</i>
<i>ACC/AHA</i>	<i>American College of Cardiology/American Heart Association.</i>
<i>ACE</i>	<i>Angiotensin converting enzyme</i>
<i>AD</i>	<i>Autosomal dominant.</i>
<i>AO</i>	<i>Aortic bulb.</i>
<i>Aort VTI</i>	<i>Time velocity integral for aortic valve.</i>
<i>AORT-VTI</i>	<i>Time velocity integral for aortic valve.</i>
<i>AR</i>	<i>Autosomal recessive.</i>
<i>ARDS</i>	<i>Adult respiratory distress syndrome</i>
<i>AT/PEAET</i>	<i>Acceleration time/ pulmonary artery ejection time.</i>
<i>BAL</i>	<i>Bronchoalveolar lavage</i>
<i>BNP</i>	<i>Brain natriuretic peptide</i>
<i>CAD</i>	<i>Coronary artery disease</i>
<i>CBC</i>	<i>Complete blood count.</i>
<i>CF</i>	<i>Cystic fibrosis.</i>
<i>chILD</i>	<i>Children's interstitial lung disease</i>
<i>CI</i>	<i>Cardiac index.</i>
<i>CNP</i>	<i>Natriuretic peptide receptor-C.</i>
<i>COPD</i>	<i>Chronic obstructive pulmonary disease</i>
<i>CRP</i>	<i>C-reactive protein.</i>
<i>CRT</i>	<i>Cardiac resynchronization therapy</i>
<i>CRT</i>	<i>Cardiac resynchronization therapy.</i>
<i>CTD</i>	<i>Connective tissue disease</i>
<i>CTD</i>	<i>Connective tissue disease.</i>
<i>CXR</i> s	<i>Chest x-rays.</i>
<i>DT</i>	<i>Deceleration time.</i>
<i>E'</i>	<i>Annular peak velocity during early diastole.</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>E/A</i>	<i>Ratio between heights of early and late diastolic flow velocity peaks for both mitral and tricuspid valves.</i>
<i>ECHO</i>	<i>Echocardiography.</i>
<i>ECM</i>	<i>Extra cellular matrix.</i>
<i>EDV</i>	<i>End diastolic volume.</i>
<i>EF%</i>	<i>Ejection fraction.</i>
<i>ELISA</i>	<i>Enzyme-linked immunosorbent assay</i>
<i>eNO</i>	<i>Exhaled nitric oxide</i>
<i>ESR</i>	<i>Erythrocyte sedimentation rate.</i>
<i>ESV</i>	<i>End systolic volume.</i>
<i>ESWSm</i>	<i>end-systolic wall stress</i>
<i>ESWSm</i>	<i>Left ventricular meridional end-systolic wall stress.</i>
<i>ET</i>	<i>Ejection time</i>
<i>ET-MV</i>	<i>Ejection time mitral valve.</i>
<i>ET-TV</i>	<i>Ejection time tricuspid valve.</i>
<i>FDA</i>	<i>Food and Drug administration</i>
<i>FEV1</i>	<i>Forced expiratory volume in one second.</i>
<i>FS%</i>	<i>Fractional shortening.</i>
<i>FVC</i>	<i>Forced vital capacity</i>
<i>HB</i>	<i>Haemoglobin.</i>
<i>HIV</i>	<i>Human Immunodeficiency virus</i>
<i>HP</i>	<i>Hypersensitivity pneumonitis</i>
<i>HP</i>	<i>Hypersensitivity pneumonitis.</i>
<i>HRCT</i>	<i>High-resolution computed tomography</i>
<i>Ht</i>	<i>Height</i>
<i>Ht</i>	<i>Height.</i>
<i>IgA</i>	<i>Immunoglobulin A</i>
<i>IgG</i>	<i>Immunoglobulin G</i>
<i>IIP</i>	<i>Idiopathic interstitial pneumonia</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>ILD</i>	<i>Interstitial lung disease</i>
<i>ILDs</i>	<i>Chronic interstitial lung diseases.</i>
<i>Indexed RA area</i>	<i>Indexed right atrium area.</i>
<i>IPF</i>	<i>Interstitial pulmonary fibrosis.</i>
<i>IV</i>	<i>Administered intravenously.</i>
<i>I.V</i>	<i>Intravenously</i>
<i>IVCT</i>	<i>Isovolumetric contraction time</i>
<i>IVMA-MA</i>	<i>Mitral valve myocardial acceleration during isovolumetric contraction.</i>
<i>IVMA-MV</i>	<i>Mitral valve myocardial acceleration during isovolumic contraction.</i>
<i>IVMA-PA</i>	<i>Pulmonary artery</i>
<i>IVMA-TV</i>	<i>Tricuspid valve myocardial acceleration during isovolumetric contraction.</i>
<i>IVRT</i>	<i>Isovolumetric relaxation time</i>
<i>IVSD</i>	<i>Interventricular septum thickness at end-diastole.</i>
<i>IVSS</i>	<i>Interventricular septum thickness at end-systole.</i>
<i>KL-6</i>	<i>Krebs von den Lunge-6 antigen</i>
<i>LA</i>	<i>Left atrium.</i>
<i>LTx</i>	<i>Lung transplantation</i>
<i>LV</i>	<i>Left ventricle.</i>
<i>LVED</i>	<i>Left ventricular end diastolic dimension.</i>
<i>LVEDPs</i>	<i>LV end-diastolic pressures</i>
<i>LVES</i>	<i>Left ventricular end systolic dimension.</i>
<i>LVIDd</i>	<i>Left ventricular internal dimension at end-diastole.</i>
<i>LVIDs</i>	<i>Left ventricular internal dimension at end-systole.</i>
<i>LVM</i>	<i>Left ventricular mass.</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>LVP Wd</i>	<i>Left ventricular posterior wall thickness at end-diastole.</i>
<i>LVP Ws</i>	<i>Left ventricular posterior wall thickness at end-systole.</i>
<i>LVRWT</i>	<i>Left ventricular relative wall thickness.</i>
<i>LVWI</i>	<i>Left ventricular work index.</i>
<i>MMP</i>	<i>Matrix metalloproteinases</i>
<i>mMRC</i>	<i>Modified Medical Research Council</i>
<i>MPI</i>	<i>Myocardial performance index</i>
<i>MPV</i>	<i>Mean platelet volume.</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>OLB</i>	<i>Open lung biopsy</i>
<i>OLB</i>	<i>Open lung biopsy.</i>
<i>PA VTI</i>	<i>Time velocity integral for pulmonary valve.</i>
<i>PAH</i>	<i>Pulmonary arterial hypertension.</i>
<i>PaO₂</i>	<i>Partial pressure of oxygen</i>
<i>PAP</i>	<i>Pulmonary artery pressure.</i>
<i>PA-VTI</i>	<i>Time velocity integral for pulmonary artery.</i>
<i>PDE5</i>	<i>Phosphodiesterase type 5</i>
<i>PDE5</i>	<i>Phosphodiesterase type 5 inhibitors.</i>
<i>PPH</i>	<i>Persistent pulmonary hypertension.</i>
<i>PVR</i>	<i>Peripheral vascular resistance.</i>
<i>RHC</i>	<i>Right heart catheterization.</i>
<i>ROC</i>	<i>Receiver operating characteristic curve.</i>
<i>RPEP/AT</i>	<i>Right ventricle pre -ejection period / right ventricle acceleration time.</i>
<i>R-sist</i>	<i>Right ventricular systolic time.</i>
<i>RSV</i>	<i>Right ventricular stroke volume.</i>
<i>RV MPI</i>	<i>Right ventricle myocardial performance index.</i>
<i>RV S/D ratio</i>	<i>Right ventricle systolic / diastolic ratio.</i>
<i>RV WI</i>	<i>Right ventricular work index.</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>RV-FAC</i>	<i>Right ventricle fractional area change.</i>
<i>RVPEP/RVET</i> ...	<i>Right ventricle pre-ejection period/ right ventricle ejection time.</i>
<i>RVRWT</i>	<i>Right ventricular relative wall thickness.</i>
<i>RVWL</i>	<i>Right ventricular work index.</i>
<i>S'</i>	<i>Annular peak velocity during systole.</i>
<i>SC</i>	<i>Subcutaneously</i>
<i>SD</i>	<i>Standard deviation.</i>
<i>SFmid</i>	<i>Midwall Shortening Fraction</i>
<i>SPSS</i>	<i>Statistical program for social science.</i>
<i>SV</i>	<i>Stroke volume.</i>
<i>TAPSE</i>	<i>Tricuspid annular plane systolic excursion.</i>
<i>TDI</i>	<i>Tissue doppler imaging.</i>
<i>Tej</i>	<i>Pulmonary ejection time.</i>
<i>TLC</i>	<i>Total leucocytic count.</i>
<i>TTE</i>	<i>Transthoracic echocardiography</i>
<i>UPPP</i>	<i>Uvulopalatopharyngoplasty</i>
<i>VATS</i>	<i>Video assisted thoracoscopy.</i>
<i>Wt</i>	<i>Weight.</i>

Abstract

Background: Pulmonary arterial hypertension (PAH) is an important determinant of morbidity, mortality and severity in chronic lung diseases children. Echocardiography is an indirect measure for PH with a limited accuracy compared to right heart catheterization and requires qualified physicians. BNP is the major hormone of the natriuretic peptide system, which is highly activated in different left and right heart diseases in the context of neurohumoral activation. In addition, in pulmonary arterial hypertension, BNP levels are elevated and seem to reflect clinical and hemodynamic status in this patient population. So, the aim of current study to detect the role of BNP in detection of pulmonary hypertension in CLDs children as objective, easy, repeatable available method.

Methods: Case-control study on thirty (30) children with Chronic lung diseases who recruited from the Pediatric chest clinic, Children hospital, Ain Shams University. We classified patients into PH and non-PH groups according to echocardiographic measurement of PAP >25mmHg. Serum BNP was assessed and correlated to echocardiographic data.

Results: Serum BNP showed a highly statistically significant difference between two groups. AS, mean level of BNP in PH group compared to non-PH group was (265.30 ± 199.83 & 40.01 ± 23.01) respectively. Moreover, BNP significantly correlated with Echocardiographic parameters that reflect RT ventricular dysfunction. BNP cut-off to diagnose PH among studied patients was > 97.5 pg/ml with sensitivity of 95%, specificity of 98%, PPV equals 98%, NPV equals 94% and accuracy 98%.

Conclusion: BNP is an objective, repeatable, easy marker can be used to diagnose pulmonary hypertension in chronic lung diseases in children.

Keywords: B-type natriuretic peptide; pulmonary hypertension; chronic lung diseases; Paediatrics; ECHO.

INTRODUCTION

Pediatric chronic lung diseases include many diseases such as: bronchiectasis, interstitial pulmonary fibrosis, cystic fibrosis, asthma, emphysema, bronchopulmonary dysplasia, sequestrated lung disease and bronchiolitis obliterans. They can be primary or secondary. They can be congenital or acquired (*Ibrahim et al., 2011*).

They represent a heterogeneous group of many distinct clinicopathological entities. Their prevalence have increased in the past decade because of the more advanced and intensive respiratory support provided for compromised children (*Rossi and Owens, 2005*).

Children with chronic diseases of the respiratory system represent a large and even growing population, there is a need for an early and reliable diagnosis of complicating pulmonary hypertension (PH) leading to additional dyspnea and increased mortality (*Hanno et al., 2006*).

Incessant exposure to hypoxemia is one of the mechanisms besides others leading to sustained pulmonary vasoconstriction and narrowing of the pulmonary vasculature. Consequently, PH develops leading to right heart enlargement with ventricular hypertrophy, and impaired cardiac function, known as cor pulmonale. Although PH potentially develops in every hypoxemic or chronic lung disease, there is still

uncertainty about the degree of a clinical relevant PH and about the time point when right heart catheterization should be initiated, as this is the method of choice to definitely diagnose PH (*Weitzenblum, 2003*).

The most accurate method for early diagnosis of PH is right heart catheterization, but it still dangerous and invasive technique, Echocardiography (ECHO) is an important modality in the noninvasive assessment of PH and has been used to screen for the disease, determine right and left heart structure and function, and assess response to therapy in persons with PH (*Galie et al., 2004*).

Although limitations to its use in PH and PAH exist, several aspects of ECHO are particularly helpful in the assessment and long-term management of patients with PH (*McGoon et al., 2004*).

BNP is the major hormone of the natriuretic peptide system, which is highly activated in different left and right heart diseases in the context of neurohumoral activation. BNP is of special interest in this field as it is predominately secreted by the cardiac ventricles. In addition, in pulmonary arterial hypertension, BNP levels are elevated and seem to reflect clinical and hemodynamic status in this patient population. There are other studies that compare between BNP and catheterization in diagnosis of PH but did not compare data